Ascendis Pharma will pay BioMarin royalties of up to 20% on navepegritide net sales through May 2030 to resolve all litigation between the two companies.

The Canadian biotech cleared a central IRB review for its Phase II LSALT peptide study, bringing five U.S. institutions closer to activation.

Alvotech's BLA for AVT80, a proposed interchangeable subcutaneous biosimilar to Entyvio, has been accepted for review by the FDA, completing its dual-presentation

The HealthTech track and two headline device demonstrations are what life sciences gets this year, with no biotech deal announced as the fifth edition opened.

The NYSE-listed musculoskeletal device maker is buying Durham-based Higgs Boson Health to build out a surgical intelligence and patient-journey platform.

BridgeBio's Attruby generated CMR evidence of cardiac structural reversal and 65 extra days alive out of hospital at three years in ATTR-CM patients.

The Nasdaq-listed biotech secured IP protection for its cannabinoid agonist's commercial formulation, extending coverage to 2041 across two active Phase 2 studies.

Autonomix Medical has been granted a US patent covering real-time feedback-guided precision neuromodulation systems, including neural ablation for cancer pain relief.

Coloplast appoints Amanda Rajkumar as Chief People Officer and moves Kerecis founder Fertram Sigurjonsson into an innovation advisory role.

The Danish medtech reported solid third-quarter trading across Chronic Care but flagged a 6% sales decline in Biologics due to reimbursement changes.

HUTCHMED's Phase III SANOVO trial met its primary endpoint in treatment-naïve MET-overexpressing EGFR-mutated NSCLC, with an encouraging early overall survival signal.

The Hong Kong-listed platform reported RMB 1.82bn in H1 2026 revenue, driven by its proprietary XingShi LLM and a fast-growing chronic disease